Guardant Health, Inc.

Equities

GH

US40131M1099

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
17.96 USD +1.53% Intraday chart for Guardant Health, Inc. +0.17% -33.60%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer CI
Transcript : Guardant Health, Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 01:00 PM
Piper Sandler Cuts Price Target on Guardant Health to $30 From $40, Maintains Overweight Rating MT
UBS Adjusts Guardant Health Price Target to $32 From $45, Maintains Buy Rating MT
Canaccord Genuity Adjusts Price Target on Guardant Health to $45 From $50, Maintains Buy Rating MT
Guardant Health Q4 Adjusted Loss Narrows as Revenue Rises MT
Transcript : Guardant Health, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Earnings Flash (GH) GUARDANT HEALTH Posts Q4 Revenue $155.1M, vs. Street Est of $150.8M MT
Guardant Health, Inc. Provides Earnings Guidance for the Year 2024 CI
Guardant Health, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Guardant Health, Inc. Announces Resignation of Mr. Samir Kaul as Member of the Board and as Member of the Compensation Committee of the Board CI
Goldman Sachs Cuts Price Target on Guardant Health to $37 From $43, Maintains Buy Rating MT
Transcript : Guardant Health, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:45 PM
Guardant Health Reports Preliminary Q4 Revenue MT
EDX Medical maintains confident outlook; implements biopsy tests AN
Guardant Health Teams Up With Hikma Pharmaceuticals to Offer Cancer Diagnostics in Middle East, North Africa MT
Guardant Health Names Terilyn Juarez Monroe as Chief People Officer MT
Guardant Health, Inc. Announces Executive Changes CI
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday MT
Guardant Health Reports Tentative Date for US FDA Advisory Panel Review of Shield Blood Test MT
Guardant Health, Inc. Announces Tentative Date of FDA Advisory Panel Review of Shield(TM) Blood Test CI
Guardant Health Insider Sold Shares Worth $152,954, According to a Recent SEC Filing MT
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities CI
Transcript : Guardant Health, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-28-2023 09:30 AM
North American Morning Briefing : Caution -2- DJ
Chart Guardant Health, Inc.
More charts
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer globally through the use of its proprietary tests, vast data sets and advanced analytics. The Company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. It also has developed Guardant360 TissueNext tissue test for advanced-stage cancer, Guardant Reveal blood test to detect residual and recurring disease in early-stage cancer patients, and Guardant360 Response blood test to predict patient response to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imaging. The Company's GuardantINFORM platform is used to help biopharmaceutical companies accelerate precision oncology drug development through the use of this in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
17.96 USD
Average target price
41.76 USD
Spread / Average Target
+132.54%
Consensus
  1. Stock
  2. Equities
  3. Stock Guardant Health, Inc. - Nasdaq
  4. News Guardant Health, Inc.
  5. Guardant Health : Reportedly Mulls Acquisition of Diagnostics Services Provider NeoGenomics